28 September 2009 17:28 [Source: ICIS news]
Differences between AlzChem's and Evonik's core businesses were cited as the reason for the sale, an Evonik spokeswoman said.?xml:namespace>
Before a sale is finalised, Germany's cartel office and Evonik's board must accept the purchase conditions, the spokeswoman said.
A timeframe for the deal has not yet been agreed, she added.
Bluo and AlzChem were unavailable for immediate comment.
Evonik recently denied a report that it was planning to sell its power production and real estate divisions to focus on its specialty chemicals business.
In July, Evonik said it was performing a portfolio analysis of all of its activities with the support of investment bank JP Morgan.
In July, Evonik said it was performing a portfolio analysis of all of its activities with the support of investment bank JP Morgan.AlzChem, based in Trostberg, in southeastern
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|